TRAIL-based therapies are now in phase I/II clinical trials http://www.clinicaltrials.gov but resistance to TRAIL by tumor cells, including ovarian cancer, may limit its therapeutic use [19-21]. Here, TNFSF10 is linked to neoplasm.